Global clinical T1D trials have been conducted to examine additional indications for the use of SGLT2 inhibitors, including canagliflozin [5], dapagliflozin [6,7,8], empagliflozin [9], and sotagliflozin (a dual SGLT1/2 inhibitor) [10,11,12], for individuals with T1D. The gene discussed is SLC5A1; the disease is type 1 diabetes mellitus.